Akebia Therapeutics Company Profile (NASDAQ:AKBA)

About Akebia Therapeutics

Akebia Therapeutics logoAkebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company's segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AKBA
  • CUSIP:
Key Metrics:
  • Previous Close: $9.09
  • 50 Day Moving Average: $8.43
  • 200 Day Moving Average: $8.62
  • 52-Week Range: $7.00 - $13.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.24
  • P/E Growth: 0.00
  • Market Cap: $166.16M
  • Outstanding Shares: 18,300,000
  • Beta: 0.8
Profitability:
  • Return on Equity: -69.90%
  • Return on Assets: -56.09%
Debt:
  • Current Ratio: 9.20%
  • Quick Ratio: 9.20%
Additional Links:
Companies Related to Akebia Therapeutics:

Analyst Ratings

Consensus Ratings for Akebia Therapeutics (NASDAQ:AKBA) (?)
Ratings Breakdown: 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $15.00 (65.20% upside)

Analysts' Ratings History for Akebia Therapeutics (NASDAQ:AKBA)
Show:
DateFirmActionRatingPrice TargetDetails
9/29/2016Brean CapitalInitiated CoverageBuy$18.00View Rating Details
8/23/2016HC WainwrightReiterated RatingBuyView Rating Details
8/11/2016JMP SecuritiesReiterated RatingMarket Perform$16.00View Rating Details
8/9/2016Credit Suisse Group AGReiterated RatingHold$8.00View Rating Details
5/8/2016Morgan StanleyReiterated RatingBuyView Rating Details
3/16/2016Needham & Company LLCLower Price TargetBuy$18.00 -> $14.00View Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$24.00 -> $16.00View Rating Details
5/12/2015NomuraReiterated RatingBuy$37.00 -> $27.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Akebia Therapeutics (NASDAQ:AKBA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/8/2016($0.57)($0.95)ViewN/AView Earnings Details
3/14/2016Q415($0.28)($0.66)$11.60 millionViewListenView Earnings Details
11/9/2015Q3($0.52)($0.68)ViewN/AView Earnings Details
8/11/2015Q215($0.51)($0.40)ViewN/AView Earnings Details
5/11/2015($0.57)($0.53)ViewN/AView Earnings Details
3/4/2015Q414($0.66)($0.52)ViewN/AView Earnings Details
11/10/2014Q314($0.45)($0.47)ViewN/AView Earnings Details
8/11/2014($0.34)($0.39)ViewN/AView Earnings Details
5/12/2014($0.38)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Akebia Therapeutics (NASDAQ:AKBA)
Current Year EPS Consensus Estimate: $-4.13 EPS
Next Year EPS Consensus Estimate: $-4.06 EPS

Dividends

Dividend History for Akebia Therapeutics (NASDAQ:AKBA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Akebia Therapeutics (NASDAQ:AKBA)
Insider Ownership Percentage: 7.95%
Institutional Ownership Percentage: 51.58%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/6/2016Duane NashDirectorSell1,980$7.48$14,810.40View SEC Filing  
7/5/2016Nicole R. HadasSVPSell1,557$7.47$11,630.79View SEC Filing  
4/4/2016Michel DahanSVPSell1,401$9.41$13,183.41View SEC Filing  
10/2/2015Nicole R HadasSVPSell1,484$8.67$12,866.28View SEC Filing  
7/2/2015Nicole R HadasSVPSell1,484$9.54$14,157.36View SEC Filing  
4/22/2015Muneer A SatterDirectorBuy420,000$8.25$3,465,000.00View SEC Filing  
4/2/2015Nicole R HadasSVPSell1,483$9.09$13,480.47View SEC Filing  
1/2/2015Nicole R HadasVPSell1,715$11.46$19,653.90View SEC Filing  
12/29/2014John P ButlerCEOBuy1,000$11.57$11,570.00View SEC Filing  
12/26/2014Duane NashDirectorSell11,933$11.23$134,007.59View SEC Filing  
12/22/2014John P ButlerCEOBuy1,000$11.92$11,920.00View SEC Filing  
12/15/2014John P ButlerCEOBuy1,000$11.34$11,340.00View SEC Filing  
12/2/2014Ronald C Renaud JrDirectorBuy5,000$11.92$59,600.00View SEC Filing  
11/26/2014Jason AmelloCFOBuy1,000$13.22$13,220.00View SEC Filing  
11/25/2014Muneer A SatterDirectorBuy5,000$13.18$65,900.00View SEC Filing  
11/24/2014Muneer A SatterDirectorBuy5,000$13.88$69,400.00View SEC Filing  
11/21/2014Muneer A SatterDirectorBuy5,000$14.73$73,650.00View SEC Filing  
11/20/2014Muneer A SatterDirectorBuy5,000$14.70$73,500.00View SEC Filing  
11/19/2014Muneer A SatterDirectorBuy5,000$14.85$74,250.00View SEC Filing  
11/18/2014Muneer A SatterDirectorBuy5,000$13.84$69,200.00View SEC Filing  
11/17/2014Muneer A SatterDirectorBuy5,000$12.94$64,700.00View SEC Filing  
11/14/2014Muneer A SatterDirectorBuy5,000$11.91$59,550.00View SEC Filing  
11/13/2014Muneer A SatterDirectorBuy5,000$11.56$57,800.00View SEC Filing  
11/12/2014John P ButlerCEOBuy1,000$10.31$10,310.00View SEC Filing  
11/12/2014Muneer A SatterDirectorBuy5,000$11.90$59,500.00View SEC Filing  
3/25/2014A/S NovoInsiderBuy182,590$17.00$3,104,030.00View SEC Filing  
3/25/2014Jason AmelloCFOBuy4,000$17.00$68,000.00View SEC Filing  
3/25/2014John P ButlerCEOBuy13,850$17.00$235,450.00View SEC Filing  
3/25/2014Muneer A SatterDirectorBuy91,295$17.00$1,552,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Akebia Therapeutics (NASDAQ:AKBA)
DateHeadline
streetinsider.com logoAkebia Therapeutics (AKBA) Announces Publication of Positive HIF Treatments Data in Renal Anemia - StreetInsider.com (NASDAQ:AKBA)
www.streetinsider.com - September 26 at 3:23 PM
4-traders.com logoAkebia Therapeutics : Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia (NASDAQ:AKBA)
www.4-traders.com - September 26 at 9:44 AM
publicnow.com logoAkebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia (NASDAQ:AKBA)
www.publicnow.com - September 26 at 9:44 AM
News IconStock Update on Earnings & Estimates for Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Frisco Fastball (NASDAQ:AKBA)
friscofastball.com - September 22 at 9:17 AM
biz.yahoo.com logoAKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:AKBA)
biz.yahoo.com - September 21 at 9:54 AM
investornewswire.com logoShares Of Akebia Therapeutics, Inc. (NASDAQ:AKBA) Expected To Hit $26 - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - September 20 at 3:25 PM
streetinsider.com logoAkebia Therapeutics (AKBA) Reports Publication of Strong Vadadustat Phase 2 Data in CKD-Related Anemia - StreetInsider.com (NASDAQ:AKBA)
www.streetinsider.com - September 20 at 9:13 AM
4-traders.com logoAkebia Therapeutics : Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease (NASDAQ:AKBA)
www.4-traders.com - September 19 at 4:20 PM
publicnow.com logoAkebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease (NASDAQ:AKBA)
www.publicnow.com - September 19 at 4:20 PM
News IconHow Analysts Rated Akebia Therapeutics Inc (NASDAQ:AKBA) Last Week? - Post News (NASDAQ:AKBA)
www.kentuckypostnews.com - September 16 at 3:25 PM
capitalcube.com logoAkebia Therapeutics, Inc. :AKBA-US: Earnings Analysis: Q2, 2016 By the Numbers : September 14, 2016 (NASDAQ:AKBA)
www.capitalcube.com - September 14 at 3:25 PM
News IconAkebia Therapeutics Incorporated (NASDAQ:AKBA) Shorted Shares Increased 1.25% After Market Selling - Frisco Fastball (NASDAQ:AKBA)
friscofastball.com - September 14 at 9:11 AM
News IconSell-side is Weighing in on Akebia Therapeutics, Inc. (NASDAQ:AKBA) Earnings & Targets - Frisco Fastball (NASDAQ:AKBA)
friscofastball.com - September 9 at 8:11 AM
finance.yahoo.com logoAkebia to Present at Upcoming Investor Conferences - Yahoo Finance (NASDAQ:AKBA)
finance.yahoo.com - September 8 at 11:43 AM
publicnow.com logoAkebia to Present at Upcoming Investor Conferences (NASDAQ:AKBA)
www.publicnow.com - September 6 at 8:31 PM
News IconStock Struggling for the Quarter: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Post News (NASDAQ:AKBA)
www.kentuckypostnews.com - September 4 at 3:22 PM
investornewswire.com logoCan Shares Of Akebia Therapeutics, Inc. (NASDAQ:AKBA) Get To $26? - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - August 29 at 4:02 PM
realistinvestor.com logoAkebia Therapeutics, Inc. (NASDAQ:AKBA) Is Expected To Post EPS Of $-1.25 - RealistInvestor.com (NASDAQ:AKBA)
www.realistinvestor.com - August 29 at 4:02 PM
live-pr.com logoNew Market Research Report: Akebia Therapeutics, Inc. (AKBA) - Financial and Strategic SWOT Analysis Review (NASDAQ:AKBA)
www.live-pr.com - August 26 at 3:24 PM
investornewswire.com logoAkebia Therapeutics, Inc. (NASDAQ:AKBA) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - August 22 at 3:27 PM
4-traders.com logoAkebia Therapeutics : Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients (NASDAQ:AKBA)
www.4-traders.com - August 22 at 8:12 AM
finance.yahoo.com logo7:04 am Akebia Therapeutics announces the publication of an analysis indicating persistently greater mortality in dialysis-dependent chronic kidney disease patients with agent hyporesponse (NASDAQ:AKBA)
finance.yahoo.com - August 22 at 8:12 AM
publicnow.com logoAkebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients (NASDAQ:AKBA)
www.publicnow.com - August 22 at 8:12 AM
finance.yahoo.com logoAKEBIA THERAPEUTICS, INC. Financials (NASDAQ:AKBA)
finance.yahoo.com - August 17 at 3:26 PM
realistinvestor.com logoAnalysts See Akebia Therapeutics, Inc. (NASDAQ:AKBA) Reporting EPS Of $-1.25 - RealistInvestor.com (NASDAQ:AKBA)
www.realistinvestor.com - August 16 at 3:25 PM
investornewswire.com logoWill Akebia Therapeutics, Inc. (NASDAQ:AKBA) Hit $26 Price Target? - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - August 15 at 3:27 PM
insidermonkey.com logoCalculating The Impact Of Akebia Therapeutics Inc (AKBA)’s Pivotals (NASDAQ:AKBA)
www.insidermonkey.com - August 12 at 3:36 PM
finance.yahoo.com logoWhy Akebia Therapeutics (AKBA) Could Be Positioned for a Slump (NASDAQ:AKBA)
finance.yahoo.com - August 12 at 11:58 AM
marketexclusive.com logoCalculating The Impact Of Akebia Therapeutics Inc (NASDAQ:AKBA)’s Pivotals (NASDAQ:AKBA)
marketexclusive.com - August 11 at 3:26 PM
News IconNoteworthy Tuesday Option Activity: AKBA, LGF, D (NASDAQ:AKBA)
www.stockoptionschannel.com - August 9 at 4:28 PM
News IconAkebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease (NASDAQ:AKBA)
ih.advfn.com - August 9 at 4:28 PM
benzinga.com logoBrean Sees Huge Upside In Akebia Shares (NASDAQ:AKBA)
www.benzinga.com - August 9 at 4:28 PM
4-traders.com logoAkebia Therapeutics : reports 2Q loss (NASDAQ:AKBA)
www.4-traders.com - August 9 at 4:28 PM
News IconAkebia Announces Second Quarter 2016 Financial Results (NASDAQ:AKBA)
www.biospace.com - August 9 at 4:28 PM
finance.yahoo.com logoAkebia's Market Potential Undervalued By The Street, Says JMP (NASDAQ:AKBA)
finance.yahoo.com - August 9 at 4:28 PM
seekingalpha.com logoAkebia misses by $0.38 - Seeking Alpha (NASDAQ:AKBA)
seekingalpha.com - August 8 at 8:52 PM
sg.finance.yahoo.com logoAkebia Therapeutics reports 2Q loss (NASDAQ:AKBA)
sg.finance.yahoo.com - August 8 at 8:52 PM
businesswire.com logoAkebia Therapeutics Appoints Scott A. Canute to its Board of Directors - Business Wire (press release) (NASDAQ:AKBA)
www.businesswire.com - August 2 at 9:01 PM
biz.yahoo.com logoAKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Fi (NASDAQ:AKBA)
biz.yahoo.com - August 2 at 9:01 PM
publicnow.com logoAkebia Therapeutics Appoints Scott A. Canute to its Board of Directors (NASDAQ:AKBA)
www.publicnow.com - August 2 at 9:01 PM
biz.yahoo.com logoAKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:AKBA)
biz.yahoo.com - July 28 at 4:07 PM
equities.com logoAkebia Therapeutics Inc. (AKBA) Jumps 5.4% on July 27 - Equities.com (NASDAQ:AKBA)
www.equities.com - July 28 at 12:03 PM
ftsenews.co.uk logoNew Broker Ratings For Akebia Therapeutics, Inc. (AKBA) - FTSE News (NASDAQ:AKBA)
www.ftsenews.co.uk - July 25 at 8:11 AM
News IconEquity Roundup: Stock Performance Focus on Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Press Telegraph (NASDAQ:AKBA)
presstelegraph.com - July 23 at 3:24 PM
News IconAkebia Therapeutics, Inc. (NASDAQ:AKBA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:AKBA)
www.engelwooddaily.com - July 21 at 3:24 PM
kcregister.com logoWhy Need to Watch: Invuity (NASDAQ:IVTY), Akebia Therapeutics (NASDAQ:AKBA), Taiwan Semiconductor ... - KC Register (NASDAQ:AKBA)
www.kcregister.com - July 20 at 11:32 AM
News IconAkebia Therapeutics Incorporated (NASDAQ:AKBA) Short Interest Increased By 0.41% - Consumer Eagle (NASDAQ:AKBA)
www.consumereagle.com - July 19 at 3:25 PM
investornewswire.com logoIs $26 Price Target Attainable For Akebia Therapeutics, Inc. (NASDAQ:AKBA)? - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - July 18 at 3:27 PM
News IconShares Moving Down on the Week: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Engelwood Daily (NASDAQ:AKBA)
www.engelwooddaily.com - July 17 at 8:10 AM
News IconAre Analysts Bullish Akebia Therapeutics Inc (NASDAQ:AKBA) After Last Week? - Consumer Eagle (NASDAQ:AKBA)
www.consumereagle.com - July 16 at 11:49 AM

Social

Akebia Therapeutics (NASDAQ:AKBA) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff